Table 3. Univariate analysis demonstrating factors associated with OS and PFS in matched patients.
| Factor | Cases (n) | OS p-value | HR (95% CI) | PFS p-value | HR (95% CI) |
|---|---|---|---|---|---|
| Treatment regimen | 0.796 | 1.074 (0.624–1.851) | 0.630 | 1.129 (0.688–1.853) | |
| TP | 41 | ||||
| CS | 41 | ||||
| Age | 0.168 | 0.674 (0.385–1.181) | 0.116 | 0.664 (0.399–1.106) | |
| age < 58 | 35 | ||||
| age ≥58 | 47 | ||||
| Sex | 0.428 | 1.338 (0.652–2.748) | 0.498 | 1.265 (0.641–2.499) | |
| Female | 12 | ||||
| Male | 70 | ||||
| ECOG PS | 0.002 | 2.416 (1.366–4.276) | 0.013 | 1.976 (1.156–3.379) | |
| 0–1 | 58 | ||||
| 2 | 24 | ||||
| T Stage | 0.000 | 4.101 (2.269–7.413) | 0.000 | 2.570 (1.546–4.273) | |
| T3 | 40 | ||||
| T4 | 42 | ||||
| N Stage | 0.002 | 2.387 (1.365–4.172) | 0.002 | 2.304 (1.369–3.876) | |
| N0 | 46 | ||||
| N1 | 36 | ||||
| M Stage | 0.010 | 2.129 (1.195–3.792) | 0.058 | 1.711 (0.982–2.981) | |
| M0 | 58 | ||||
| M1 | 24 | ||||
| Clinical Stage | 0.000 | 1.892 (1.321–2.708) | 0.009 | 1.537 (1.111–2.125) | |
| II | 25 | ||||
| III | 33 | ||||
| IVa | 24 | ||||
| Tumor Location | 0.173 | 1.305 (0.890–1.913) | 0.082 | 1.364 (0.061–1.937) | |
| Upper-third | 38 | ||||
| Middle-third | 30 | ||||
| Lower-third | 14 | ||||
| Differentiation | 0.255 | 0.806 (0.556–1.169) | 0.327 | 0.842 (0.597–1.187) | |
| Well | 19 | ||||
| Fairly | 37 | ||||
| Poorly | 26 | ||||
| Tumor Length (cm) | 0.252 | 1.396 (0.789–2.470) | 0.082 | 1611 (0.941–2.758) | |
| < 5 | 32 | ||||
| ≥ 5 | 50 | ||||
| Weight Loss | 0.479 | 1.233 (0.690–2.203) | 0.683 | 1.119 (0.653–1.919) | |
| ≤ 10% | 57 | ||||
| > 10% | 25 | ||||
| Clinical Response | 0.000 | 3.898 (2.171–6.997) | 0.000 | 3.057 (1.825–5.121) | |
| CR | 41 | ||||
| Non-CR | 41 |
Abbreviations: n: number of patients; OS: overall survival; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval, CR: complete response.